PRESS RELEASE

Q3 2026 — Press release

Q3 2026PDF · 13 pages313 KB
- 1 -
News Release
____________________________________________________________________________
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial
Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline
Sales Growth Reflects Continued Strength in Oncology and Animal Health, Plus
Contributions From Other Products in Broader Portfolio, Including WINREVAIR
Financial Highlights
- 	Total Worldwide Sales Were $18.1 Billion (5% Growth; 4% Growth ex-FX)
o 	KEYTRUDA/KEYTRUDA QLEX1 Sales Were $8.6 Billion (6% Growth; 6%
Growth ex-FX); Includes KEYTRUDA QLEX Sales of $830 Million
o 	WINREVAIR Sales Were $694 Million (93% Growth; 94% Growth ex-FX)
o 	Animal Health Sales Were $1.7 Billion (4% Growth; 3% Growth ex-FX)
- 	GAAP EPS Was $2.04; Non-GAAP EPS Was $2.49; GAAP and Non-GAAP EPS
Include a One-Time Charge of $0.12 per Share Related to a Global License Agreement
With SciBrunch
Pipeline & Portfolio Highlights
- 	Presented First-Time Pivotal Data From Phase 3 Trials Across Robust Oncology
Pipeline at ESMO Congress 2026, Including:
o 	TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (sac-TMT) in Certain
Patients With Advanced or Recurrent Endometrial Cancer; U.S. FDA Accepted
for Priority Review a Biologics License Application Based on These Data
o 	INTerpath-001 Trial Evaluating Intismeran Autogene Plus KEYTRUDA as
Adjuvant Treatment for Patients With Resected Stage IIB-IV Melanoma, in
Collaboration With Moderna
- 	Announced Positive Phase 2b Results in Moderate to Severe Hidradenitis Suppurativa
From Clinical Study of Investigational Immunology Candidate Tulisokibart
- 	Presented One-Year Results From Phase 2b/3 BRUNELLO Trial Evaluating Remigromig
in Adults With Diabetic Macular Edema
Full-Year 2026 Financial Outlook
- 	Narrows and Raises the Midpoint of Worldwide Sales Range; Now Expects Sales To Be
Between $66.8 Billion and $67.3 Billion
1 Available in some markets as KEYTRUDA SC.

-- 1 of 13 --

- 2 -
- 	Narrows and Raises Expected Non-GAAP EPS Range To Be Between $2.77 and $2.82;
Outlook Now Includes One-Time Charge of $0.12 per Share Related to the Global
License Agreement With SciBrunch
RAHWAY, N.J., Oct. 29, 2026 – Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as
MSD outside the United States and Canada, today announced financial results for the third
quarter of 2026.
“Our science-led strategy is transforming our business,” said Robert M. Davis, chairman
and chief executive officer. “The potentially practice-changing advances in oncology presented
at last weekend’s ESMO meeting, including new data for our antibody-drug conjugate sac-TMT
and the first Phase 3 validation of a therapeutic cancer vaccine, further clinically de-risk the
substantial long-term opportunity of our late-phase pipeline. With positive momentum across
multiple therapeutic areas, I’m increasingly confident in our ability to deliver long-term value for
patients and shareholders.”
Financial Summary
$ in millions, except EPS amounts
Third Quarter
2026 	2025 	Change
Change Ex-
Exchange
Sales 	$18,085 	$17,276 	5% 	4%
GAAP net income2 	5,065 	5,785 	-12% 	-14%
Non-GAAP net income that excludes certain items2,3* 	6,159 	6,448 	-4% 	-5%
GAAP EPS 	2.04 	2.32 	-12% 	-13%
Non-GAAP EPS that excludes certain items3* 	2.49 	2.58 	-3% 	-5%
*Refer to table on page 7.
For the third quarter of 2026, Generally Accepted Accounting Principles (GAAP)
earnings per share (EPS) assuming dilution was $2.04 and non-GAAP EPS was $2.49. Both
GAAP and non-GAAP EPS in the third quarter of 2026 include a one-time charge of $0.12 per
share related to a global license agreement with SciBrunch Therapeutics Co., Ltd. (SciBrunch).
Both GAAP and non-GAAP EPS in the third quarter of 2025 include a charge of $0.10 per share
for a milestone payment to LaNova Medicines Ltd. (LaNova, acquired by Sino
Biopharmaceutical Limited) associated with the technology transfer for MK-2010.
Non-GAAP EPS excludes acquisition- and divestiture-related costs and costs related to
restructuring programs, as well as income and losses from investments in equity securities.
Non-GAAP EPS in the third quarter of 2025 also excludes tax expense relating to audit reserve
adjustments.
2 Net income attributable to the Company.
3 The Company is providing certain 2026 and 2025 non-GAAP information that excludes certain items because of the nature of
these items and the impact they have on the analysis of underlying business performance and trends. Management believes that
providing this information enhances investors’ understanding of the Company’s results because management uses non-GAAP
results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to
measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior
management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in
addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-
GAAP adjustments, see Table 2a attached to this release.

-- 2 of 13 --

- 3 -
Year-to-date results can be found in the attached tables.
Third-Quarter Sales Performance
The following table reflects sales of the Company’s top products and significant
performance drivers.
Third Quarter
$ in millions 	2026 	2025 	Change
Change Ex-
Exchange 	Commentary
Total Sales 	$18,085 	$17,276 	5% 	4%
Pharmaceutical 	16,268 	15,611 	4% 	4%
Increase primarily driven by growth in
KEYTRUDA/KEYTRUDA QLEX,
WINREVAIR, GARDASIL/GARDASIL 9,
WELIREG, ENFLONSIA and the
inclusion of OHTUVAYRE sales. Growth
benefited from the timing of purchases
by approximately $550 million. Growth
was partially offset by declines in
BRIDION, JANUVIA/JANUMET and
LAGEVRIO, as well as lower alliance
revenue related to Koselugo.
KEYTRUDA/
KEYTRUDA QLEX 	8,601 	8,147 	6% 	6%
Growth primarily driven by strong global
uptake in earlier-stage indications
including triple-negative breast cancer,
cervical cancer, head and neck cancer
and bladder cancer, as well as higher
global demand in metastatic indications,
including urothelial cancer. Timing of
wholesaler purchases unfavorably
affected sales in the U.S. but was largely
offset by a benefit from increased
inventory in the channel. Sales of
KEYTRUDA QLEX were $830 million.
GARDASIL/GARDASIL 9 	1,995 	1,749 	14% 	14%
Increase primarily due to higher sales in
the U.S. reflecting favorable public-
sector purchasing patterns and higher
net pricing.
PROQUAD, M-M-R II and
VARIVAX 	730 	684 	7% 	7%
Increase primarily due to higher demand
in certain European markets.
WINREVAIR 	694 	360 	93% 	94%
Growth primarily reflects higher demand
and favorable wholesaler and specialty
pharmacy purchasing patterns in the
U.S., as well as launch uptake in certain
international markets, particularly in
Europe and Japan.
JANUVIA/JANUMET 	380 	624 	-39% 	-39%
Decline primarily driven by lower
demand due to generic competition
following loss of market exclusivity in the
U.S.
Lynparza* 	352 	379 	-7% 	-7%
Decline primarily due to lower net pricing
in the U.S. and lower demand and
pricing in China.
PREVYMIS 	347 	266 	30% 	31%
Increase primarily due to higher demand
globally.

-- 3 of 13 --

- 4 -
WELIREG 	307 	196 	56% 	58%
Growth primarily driven by higher
demand in the U.S. and continued
launch uptake in international markets,
particularly in Japan.
Lenvima* 	287 	258 	11% 	11%
Growth primarily due to higher demand
in the U.S.
CAPVAXIVE 	263 	244 	8% 	7%
Increase primarily driven by launch
uptake in several international markets,
particularly in Asia Pacific and Europe,
partially offset by lower sales in the U.S.
reflecting lower adult pneumococcal
vaccination rates and lower net pricing.
ENFLONSIA 	187 	79 	138% 	136%
Increase primarily driven by seasonal
demand and associated inventory build
in the U.S. and certain international
markets.
OHTUVAYRE 	184 	- 	- 	-
Product obtained as part of the
Company's October 2025 acquisition of
Verona Pharma plc.
BRIDION 	144 	439 	-67% 	-67%
Decline primarily driven by lower
demand in the U.S. due to generic
competition following loss of market
exclusivity.
LAGEVRIO 	17 	138 	-88% 	-88%
Decline largely due to lower demand in
Japan.
Animal Health 	1,676 	1,615 	4% 	3%
Growth attributable to both Livestock and
Companion Animal product portfolios.
Livestock 	1,048 	1,023 	2% 	2%
Growth primarily driven by higher
demand for poultry products.
Companion Animal 	628 	592 	6% 	6%
Growth largely driven by new product
launches. Sales of BRAVECTO line of
products were $264 million and $262
million in the current and prior-year
quarters, respectively, which represents
an increase of 1%, or flat excluding
impact of foreign exchange.
Other Revenues** 	141 	50 	185% 	-25%
Increase primarily due to favorable
impact of revenue-hedging activities,
partially offset by lower revenue from
third-party manufacturing arrangements.
*Alliance revenue for this product represents the Company’s share of profits, which are product sales net of cost of sales and
commercialization costs.
**Other revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities.
In addition, Koselugo alliance revenue was $13 million in the third quarter of 2026
compared with $214 million in the third quarter of 2025. The decrease was due to an
amendment to the collaboration agreement with AstraZeneca in 2025, which discontinued the
provisions whereby the Company shared revenue and costs with AstraZeneca, and revised the
payment structure, resulting in the Company’s recognition of a $150 million upfront payment and
a $50 million regulatory milestone in the third quarter of 2025.

-- 4 of 13 --

- 5 -
Third-Quarter Expense and Related Information
The table below presents selected expense information.
$ in millions 	GAAP
Acquisition-
and
Divestiture-
Related
Costs4
Restructuring
Costs
(Income)
Loss From
Investments
in Equity
Securities
Non-
GAAP3
Third Quarter 2026
Cost of sales 	$4,892 	$1,140 	$396 	$- 	$3,356
Selling, general and administrative 	2,886 	24 	- 	- 	2,862
Research and development 	4,537 	3 	1 	- 	4,533
Restructuring costs 	184 	- 	184 	- 	-
Other (income) expense, net 	27 	- 	- 	(393) 	420
Third Quarter 2025
Cost of sales 	$3,855 	$621 	$110 	$- 	$3,124
Selling, general and administrative 	2,633 	34 	- 	- 	2,599
Research and development 	4,234 	4 	233 	- 	3,997
Restructuring costs 	47 	- 	47 	- 	-
Other (income) expense, net 	(238) 	- 	- 	(344) 	106
GAAP Expense, EPS and Related Information
Gross margin was 72.9% for the third quarter of 2026 compared with 77.7% for the third
quarter of 2025. The decrease was primarily due to higher amortization of intangible assets,
restructuring costs and production costs.
Selling, general and administrative (SG&A) expenses were $2.9 billion in the third
quarter of 2026, an increase of 10% compared with the third quarter of 2025. The increase was
primarily due to higher administrative costs, as well as higher promotional costs in support of
product launches.
Research and development (R&D) expenses were $4.5 billion in the third quarter of
2026, an increase of 7% compared with the third quarter of 2025. The increase was primarily
due to a $400 million charge related to a global license agreement with SciBrunch and higher
clinical development spending, partially offset by lower restructuring costs and a $200 million
reduction in R&D expenses as part of a funding agreement with Blackstone Life Sciences
(Blackstone). R&D expenses in the third quarter of 2025 include a $300 million charge for a
milestone payment to LaNova for the completion of the technology transfer for MK-2010.
Other (income) expense, net, was $27 million of expense in the third quarter of 2026
compared with $238 million of income in the third quarter of 2025. The unfavorability was
primarily due to higher net interest expense.
4 Reflects expenses related to business combinations, including the amortization of intangible assets, intangible asset impairment
charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent
consideration. Also includes integration, transaction and certain other costs associated with acquisitions and divestitures, as well
as amortization of intangible assets related to collaborations, licensing arrangements and asset acquisitions, and recognition of fair
value step-up to inventories for asset acquisitions.

-- 5 of 13 --

- 6 -
The effective income tax rate for the third quarter of 2026 was 8.9%, reflecting the
favorable impacts of certain discrete items, as well as jurisdictional mix of income and expense.
GAAP EPS was $2.04 for the third quarter of 2026 compared with $2.32 for the third
quarter of 2025. The decrease was primarily driven by higher operating expenses, reflecting
increased investments to advance the R&D pipeline and support product launches, higher
amortization of intangible assets, higher net interest expense and increased restructuring costs,
partially offset by operational strength in the business and a lower effective income tax rate.
Non-GAAP Expense, EPS and Related Information
Non-GAAP gross margin was 81.4% for the third quarter of 2026 compared with 81.9%
for the third quarter of 2025. The decrease was primarily due to higher production costs.
Non-GAAP SG&A expenses were $2.9 billion in the third quarter of 2026, an increase of
10% compared with the third quarter of 2025. The increase was primarily due to higher
administrative costs, as well as higher promotional costs in support of product launches.
Non-GAAP R&D expenses were $4.5 billion in the third quarter of 2026, an increase of
13% compared with the third quarter of 2025. The increase was primarily due to a $400 million
charge related to a global license agreement with SciBrunch and higher clinical development
spending, partially offset by a $200 million reduction in R&D expenses as part of a funding
agreement with Blackstone. R&D expenses in the third quarter of 2025 include a $300 million
charge for a milestone payment to LaNova for the completion of the technology transfer for MK-
2010.
Non-GAAP other (income) expense, net, was $420 million of expense in the third quarter
of 2026 compared with $106 million of expense in the third quarter of 2025. The unfavorability
was primarily due to higher net interest expense.
The non-GAAP effective income tax rate for the third quarter of 2026 was 10.9%,
reflecting the favorable impacts of certain discrete items, as well as jurisdictional mix of income
and expense.
Non-GAAP EPS was $2.49 for the third quarter of 2026 compared with $2.58 for the
third quarter of 2025. The decrease was primarily driven by higher operating expenses,
reflecting increased investments to advance the R&D pipeline and support product launches,
and higher net interest expense, partially offset by operational strength in the business and a
lower effective income tax rate.

-- 6 of 13 --

- 7 -
A reconciliation of GAAP to non-GAAP net income and EPS is provided in the table that
follows.
Pipeline and Portfolio Highlights
In the third quarter, the Company achieved key regulatory and clinical milestones to
meaningfully advance its broad and diverse pipeline.
• 	Oncology:
o 	U.S. Food and Drug Administration (U.S. FDA) approved WELIREG plus
Lenvima, in collaboration with Eisai, for certain previously treated adult patients
with advanced renal cell carcinoma with a clear cell component (ccRCC), based
on Phase 3 LITESPARK-011 trial.
§ 	Approval represents first approved combination of an oral hypoxia-
inducible factor-2 alpha inhibitor and a multi-targeted vascular endothelial
growth factor tyrosine kinase inhibitor (TKI) for these patients.
o 	In October, U.S. FDA accepted a Biologics License Application (BLA) seeking
approval of sac-TMT for the treatment of adult patients with endometrial cancer
who have previously received platinum containing chemotherapy and a
programmed death receptor 1 or programmed death ligand 1 inhibitor, separately
or in combination, based on Phase 3 TroFuse-005 trial.
§ 	U.S. FDA set Prescription Drug User Fee Act (PDUFA) date of June 15,
2027. The Company is in discussions with the U.S. FDA and is hopeful
for an earlier approval.
o 	In October, European Commission (EC) approved KEYTRUDA plus Padcev as
perioperative treatment for adults with resectable muscle-invasive bladder cancer
(MIBC), based on Phase 3 KEYNOTE-B15 trial.
5 Includes the estimated income tax impacts on the reconciling items based on applying the statutory rate of the originating territory
of the non-GAAP adjustments for all periods presented. Amount in the third quarter of 2025 also includes $86 million of tax expense
relating to audit reserve adjustments.
Third Quarter
$ in millions, except EPS amounts 	2026 	2025
EPS
GAAP EPS 	$2.04 	$2.32
Difference 	0.45 	0.26
Non-GAAP EPS that excludes items listed below3 	$2.49 	$2.58
Net Income
GAAP net income2 	$5,065 	$5,785
Difference 	1,094 	663
Non-GAAP net income that excludes items listed below2,3 	$6,159 	$6,448
Excluded Items:
Acquisition- and divestiture-related costs4 	$1,167 	$659
Restructuring costs 	581 	390
Income from investments in equity securities 	(393) 	(344)
Decrease to net income before taxes 	1,355 	705
Estimated income tax (benefit) expense5 	(261) 	(42)
Decrease to net income 	$1,094 	$663

-- 7 of 13 --

- 8 -
o 	Ministry of Health, Labor and Welfare in Japan approved subcutaneous
pembrolizumab and berahyaluronidase alfa injection under the trademark
KEYJECT (marketed as KEYTRUDA QLEX in the U.S.) for all KEYTRUDA
indications approved in Japan, based on Phase 3 MK-3475A-D77 trial.
o 	At the European Society for Medical Oncology (ESMO) Congress 2026 in
October, positive new data were presented during three late-breaking
Presidential Symposia across three Phase 3 trials from the Company’s robust
oncology pipeline and portfolio, including:
§ 	Results from Phase 3 TroFuse-005 trial evaluating sac-TMT for patients
with advanced or recurrent endometrial cancer previously treated with
chemotherapy and anti-PD-1/L1 immunotherapy.
§ 	Results from Phase 3 INTerpath-001 trial, in collaboration with Moderna,
Inc. (Moderna), evaluating adjuvant treatment with intismeran autogene
(intismeran; V940 or mRNA-4157) in combination with KEYTRUDA.
§ 	Results from Phase 3 KEYNOTE-C93 trial evaluating KEYTRUDA
monotherapy versus platinum doublet chemotherapy as a first-line
treatment for certain patients with mismatch repair deficient (dMMR)
advanced or recurrent endometrial cancer who had not previously
received systemic chemotherapy or who experienced recurrence more
than six months after completing prior adjuvant therapy.
§ 	In addition, data were presented from Phase 3 OptiTROP studies in
China, led by Kelun-Biotech, evaluating sac-TMT in non-small cell lung
cancer (NSCLC), including:
• 	Results from the OptiTROP-Lung06 study as first-line treatment
for PD-L1-negative advanced non-squamous NSCLC.
• 	Final overall survival data from the OptiTROP-Lung04 study in
epidermal growth factor receptor (EGFR)-mutated NSCLC
following progression on EGFR TKIs.
o 	Ifinatamab deruxtecan (I-DXd) Biologics License Application (BLA), in
collaboration with Daiichi Sankyo, for certain patients with previously treated
extensive-stage small cell lung cancer (ES-SCLC) was voluntarily withdrawn.
• 	Vaccines and Infectious Diseases:
o 	U.S. FDA accepted a supplemental BLA (sBLA) for ENFLONSIA to expand its
indication to include prevention of respiratory syncytial virus (RSV) lower
respiratory tract disease (LRTD) in children under 2 years of age at increased
risk for severe RSV disease through their second RSV season, based on Phase
3 SMART trial.
§ 	U.S. FDA set PDUFA date of March 22, 2027.
§ 	Applications to expand marketing authorization for ENFLONSIA for same
population in Europe and Japan, based on Phase 3 SMART trial, have
also been accepted.
o 	U.S. FDA accepted a supplemental New Drug Application (sNDA) for IDVYNSO
for the treatment of certain adults with HIV-1 infection who had not previously

-- 8 of 13 --

- 9 -
received antiretroviral treatment, based on Phase 3 P053 trial. U.S. FDA also
accepted an sNDA to include 96-week data for IDVYNSO in certain virologically
suppressed adults, based on the Phase 3 P051 and P052 trials.
§ 	U.S. FDA set a PDUFA date for both sNDAs of April 22, 2027.
• 	Cardiometabolic, Respiratory and Specialty:
o 	U.S. FDA approved an update to U.S. product label for WINREVAIR to include
efficacy and safety data from the Phase 3 HYPERION trial evaluating adults
recently diagnosed with pulmonary arterial hypertension (PAH, World Health
Organization [WHO] Group 1 pulmonary hypertension).
§ 	In HYPERION, in patients diagnosed with PAH in the last 12 months,
adding WINREVAIR on top of background therapy reduced the risk of
clinical worsening events compared to placebo.
• 	Immunology:
o 	Presented results from Phase 2b study of tulisokibart in adults with moderate to
severe hidradenitis suppurativa (HS).
• 	Ophthalmology:
o 	At the American Academy of Ophthalmology (AAO) 2026 Annual Meeting in
October, presented for the first time one-year results from Phase 2b/3
BRUNELLO trial evaluating remigromig, an investigational, tetravalent, tri-specific
antibody designed to agonize the Wingless-related integration site (Wnt)
pathway, in adults with diabetic macular edema (DME).
• 	Business Development:
o 	Announced an exclusive global license agreement with SciBrunch for MK-2690
(SPR2015), an investigational preclinical oral KRAS G12D (ON) inhibitor.
Notable recent news releases on the Company’s pipeline and portfolio are provided in
the table that follows. Visit the News Releases section of the Company’s website to read the
releases.*
Oncology
Sac-TMT Reduced Risk of Death by 32% and Risk of Disease Progression or Death by 41%
Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial
Cancer; Results From Phase 3 TroFuse-005 Trial
The Company and Moderna Presented Results From Landmark Phase 3 INTerpath-001 Trial
for Intismeran Plus KEYTRUDA at ESMO 2026 Presidential Symposium; Intismeran Plus
KEYTRUDA Significantly Reduced Risk of Recurrence or Death by 42% (HR=0.58 [95% CI,
0.45–0.75]; Two-Sided p<0.001) Compared to KEYTRUDA Alone for Patients With Completely
Resected Stage IIB-IV Melanoma
KEYTRUDA as Monotherapy Reduced Risk of Disease Progression or Death by 43% for
Certain Patients With Advanced or Recurrent Endometrial Cancer With dMMR Tumors
Compared to Chemotherapy; Results From Phase 3 KEYNOTE-C93 Trial
U.S. FDA Approved WELIREG Plus Lenvima for Certain Previously Treated Adult Patients With
ccRCC; Based on Results From Phase 3 LITESPARK-011 Trial, Presented at ESMO

-- 9 of 13 --

- 10 -
KEYTRUDA QLEX Approved in Japan for Subcutaneous Administration for All KEYTRUDA
Indications Approved in Japan; Based on Results From Phase 3 MK-3475A-D77 Trial
EC Approved KEYTRUDA Plus Padcev as Perioperative Treatment for Adults With Resectable
MIBC; Based on Results From Phase 3 KEYNOTE-B15 Trial
I-DXd BLA for Certain Patients With ES-SCLC Voluntarily Withdrawn
The Company Entered Into Exclusive Global License Agreement With SciBrunch for SPR2015,
an Investigational Oral KRAS G12D (ON) Inhibitor
Vaccines and
Infectious Diseases
U.S. FDA Accepted sBLA for ENFLONSIA to Update Its RSV LRTD Indication to Include
Children Under 2 Years at Increased Risk for Severe RSV for Their Second Season; Based on
Results From Phase 3 SMART Trial; FDA Set PDUFA Date of March 22, 2027
Cardiometabolic,
Respiratory and
Specialty
U.S. FDA Approved Update to the Label for WINREVAIR to Include Data From the Phase 3
HYPERION Trial Evaluating Adults Recently Diagnosed With PAH (PAH, WHO Group 1
Pulmonary Hypertension)
Immunology Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With
Moderate to Severe HS
Ophthalmology
The Company Presented One-Year Results From Pivotal Phase 2b/3 BRUNELLO Study
Evaluating Remigromig, a Tri-Specific Agonist of the Wnt Pathway, in Adults With DME, at AAO
2026
*References in the above news release titles have been modified for the purpose of this announcement.
Sustainability Highlights
The Company’s 2025/2026 Purpose for Progress Impact Report provided a
comprehensive view of the Company’s measurable progress across its sustainability priorities,
including achieving all goals targeted for completion by 2025. The Company also introduced
new targets for 2030, including a goal to reach 100 million people with access solutions that
close gaps in care by 2030.
Full-Year 2026 Financial Outlook
The following table summarizes the Company’s full-year financial outlook.
Full Year 2026
Updated 	Prior
Sales* 	$66.8 billion to $67.3 billion 	$66.3 billion to $67.3 billion
Non-GAAP Gross margin3 	Approximately 81% 	Approximately 81%
Non-GAAP Operating expenses3** 	$42.4 billion to $42.9 billion 	$42.0 billion to $42.7 billion
Non-GAAP Other (income) expense, net3 	Approximately $1.4 billion expense 	Approximately $1.4 billion expense
Non-GAAP Effective income tax rate3 	32.0% to 33.0% 	35.0% to 36.0%
Non-GAAP EPS3*** 	$2.77 to $2.82 	$2.66 to $2.76
Share count (assuming dilution) 	Approximately 2.48 billion 	Approximately 2.48 billion
*The Company does not have any non-GAAP adjustments to sales.
**Includes one-time R&D charges of $9.0 billion for the acquisition of Cidara Therapeutics, Inc. (Cidara), $5.7 billion for the acquisition of
Terns Pharmaceuticals, Inc. (Terns), and $400 million related to the global license agreement with SciBrunch. Outlook does not assume
any additional significant potential business development transactions.
***Includes one-time charges of $3.62 per share for the acquisition of Cidara, $2.31 per share for the acquisition of Terns, and $0.12 per
share related to the global license agreement with SciBrunch.
The Company has not provided a reconciliation of forward-looking non-GAAP gross
margin, non-GAAP operating expenses, non-GAAP other (income) expense, net, non-GAAP
effective income tax rate and non-GAAP EPS to the most directly comparable GAAP measures,
given it cannot predict with reasonable certainty the amounts necessary for such a
reconciliation, including intangible asset impairment charges, legal settlements, and income and
losses from investments in equity securities either owned directly or through ownership interests

-- 10 of 13 --

- 11 -
in investment funds, without unreasonable effort. These items are inherently difficult to forecast
and could have a significant impact on the Company’s future GAAP results.
The Company now anticipates full-year 2026 sales to be between $66.8 billion and
$67.3 billion, including a positive impact from foreign exchange of approximately 1% at mid-
October 2026 exchange rates.
The Company now expects the full-year non-GAAP effective income tax rate to be
between 32.0% and 33.0%, including the impact of the non-tax-deductible one-time charges for
the acquisitions of Cidara and Terns.
The Company now expects full-year 2026 non-GAAP EPS to be between $2.77 and
$2.82, including a positive impact from foreign exchange of approximately $0.15 per share at
mid-October 2026 exchange rates. This range includes one-time charges of $9.0 billion, or
$3.62 per share, related to the acquisition of Cidara; $5.7 billion, or $2.31 per share, related to
the acquisition of Terns; and $400 million, or $0.12 per share, related to the global license
agreement with SciBrunch. The charge related to SciBrunch was not previously included in the
outlook. In 2025, non-GAAP EPS of $8.98 was negatively impacted by one-time charges of
$0.20 per share in the aggregate related to certain business development transactions.
Consistent with past practice, the financial outlook does not assume additional
significant potential business development transactions.
Earnings Conference Call
Investors, journalists and the general public may access a live audio webcast of the call
on Thursday, Oct. 29, at 9 a.m. EDT via this weblink. A replay of the webcast, along with the
sales and earnings news release, supplemental financial disclosures and slides highlighting the
results, will be available on the Company’s website.
All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Free)
or (517) 308-9448 and using the access code 9818590.
About Our Company
At Merck & Co., Inc., Rahway, N.J., USA, known as MSD outside of the United States
and Canada, we are unified around our purpose: We use the power of leading-edge science to
save and improve lives around the world. For more than 130 years, we have brought hope to
humanity through the development of important medicines and vaccines. We aspire to be the
premier research-intensive biopharmaceutical company in the world – and today, we are at the
forefront of research to deliver innovative health solutions that advance the prevention and
treatment of diseases in people and animals. We foster a diverse and inclusive global workforce
and operate responsibly every day to enable a safe, sustainable and healthy future for all
people and communities.

-- 11 of 13 --

- 12 -
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “Company”) includes
“forward-looking statements” within the meaning of the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These statements are based upon the current
beliefs and expectations of the Company’s management and are subject to significant risks and
uncertainties. There can be no guarantees with respect to pipeline candidates that the
candidates will receive the necessary regulatory approvals or that they will prove to be
commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties
materialize, actual results may differ materially from those set forth in the forward-looking
statements.
Risks and uncertainties include but are not limited to, general industry conditions and
competition; general economic factors, including interest rate and currency exchange rate
fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory approval; the Company’s ability to
accurately predict future market conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk; dependence on the effectiveness of the
Company’s patents and other protections for innovative products; and the exposure to litigation,
including patent litigation, and/or regulatory actions.
The Company undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise. Additional factors
that could cause results to differ materially from those described in the forward-looking
statements can be found in the Company’s Annual Report on Form 10-K for the year ended
December 31, 2025 and the Company’s other filings with the Securities and Exchange
Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Appendix
Generic product names are provided below.
Pharmaceutical
BRIDION (sugammadex)
CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine)
ENFLONSIA (clesrovimab-cfor)
GARDASIL (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine,
Recombinant)
GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
IDVYNSO (doravirine/islatravir)
JANUMET (sitagliptin and metformin HCl)
JANUVIA (sitagliptin)
KEYTRUDA (pembrolizumab)
KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph)

-- 12 of 13 --

- 13 -
LAGEVRIO (molnupiravir)
Lenvima (lenvatinib)
Lynparza (olaparib)
M-M-R II (Measles, Mumps and Rubella Virus Vaccine Live)
OHTUVAYRE (ensifentrine)
PREVYMIS (letermovir)
PROQUAD (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)
VARIVAX (Varicella Virus Vaccine Live)
WELIREG (belzutifan)
WINREVAIR (sotatercept-csrk)
Animal Health
BRAVECTO (fluralaner)
###
Media Contacts: 	Investor Contacts:
Michael Levey
michael.levey@msd.com
John Cummins
john.cummins2@msd.com
Peter Dannenbaum
(732) 594-1579
Steven Graziano
(732) 594-1583

-- 13 of 13 --